Haemonetics (HAE) Equity Average (2010 - 2026)

Haemonetics' Equity Average history runs 17 years deep, the most recent figure standing at $853.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 1.15% year-over-year to $853.9 million; the TTM figure through Mar 2026 stood at $853.9 million (down 1.15% YoY), while the FY2026 annual figure was $808.6 million, down 9.19% from the prior year.
• Equity Average was $853.9 million for Q1 2026 at Haemonetics, down from $880.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $951.6 million in Q1 2024 to a low of $714.7 million in Q1 2022.
• Historically, Equity Average has averaged $841.0 million across 5 years, with a median of $858.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Equity Average rose 22.06% in 2023, then fell 9.23% in 2025.
• A 5-year view of Equity Average shows it stood at $752.5 million in 2022, then rose by 22.06% to $918.5 million in 2023, then decreased by 2.79% to $892.9 million in 2024, then decreased by 1.4% to $880.3 million in 2025, then dropped by 3.0% to $853.9 million in 2026.
• The last three Equity Average figures came in at $853.9 million (Q1 2026), $880.3 million (Q4 2025), and $865.7 million (Q3 2025), per Business Quant data.